<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286778</url>
  </required_header>
  <id_info>
    <org_study_id>F-9892131B</org_study_id>
    <nct_id>NCT02286778</nct_id>
  </id_info>
  <brief_title>Eradication of Malignant Carcinoma in the Breast Tissue</brief_title>
  <official_title>The Eradication of Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimal Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optimal Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the findings of an early study and expand our
      knowledge of treating Malignant Carcinoma in the Breast Tissue Using an ATP
      (Adenosine-5'-Triphosphate) Inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants tumor free</measure>
    <time_frame>12 months</time_frame>
    <description>assessed by MRI</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Acetogenins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Acetogenins BID for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: No Acetogenins BID for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acetogenins</intervention_name>
    <description>Acetogenins BID for 12 months</description>
    <arm_group_label>Acetogenins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of breast cancer

          -  Referred to the study by their treating physician

        Exclusion Criteria:

          -  Any type of treatment for breast cancer before starting the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Shaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimal Health Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Osguthorpe, ND</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimal Health Research</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>November 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
